Preethi Sankaran
Fulcrum Therapeutics (United States)(US)Atossa Therapeutics (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Immunotherapy and Immune Responses, Radiopharmaceutical Chemistry and Applications, Cancer, Stress, Anesthesia, and Immune Response
Most-Cited Works
- → Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release(2021)65 cited
- → Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies(2019)40 cited
- → Crystal Structure of Human BCMA in complex with UniAb(TM) VH(2019)37 cited
- → A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells(2021)35 cited
- → Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade(2024)9 cited
- → Abstract 4159: The COX-2/PGE2 pathway as a mediator of resistance to anti-PD-1 therapy(2023)4 cited
- → 288 The COX-2 pathway as a mediator of resistance to anti-PD-1 therapy(2021)4 cited
- → A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release.(2019)2 cited
- → CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo(2024)1 cited
- → Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release.(2020)1 cited